Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors

✍ Scribed by F. Belardelli; V. Ciolli; U. Testa; E. Montesoro; D. Bulgarinl; E. Proietti; P. Borghi; P. Sestili; C. Locardi; C. Peschle; I. Gresser

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: French
• Weight: 965 KB
• Volume: 44
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910440629

✦ Synopsis

We have studied the anti-tumor effects of human recombinant IL2, alone or in association with LAKcells, in mice transplanted subcutaneously (s.c.) with the following syngeneic tumors: highly metastatic Friend leukemia cells (FLC), nonmetastatic FLC, lymphoma RBL-5 cells and HeJ16 fibrosarcoma cells. In these tumor models, peri-tumoral injections of IL-2 were more effective in inhibiting tumor growth than a systemic treatment. Although S.C. IL-2 treatment resulted in marked inhibition of tumor growth in mice injected S. C. with highly metastatic FLC, it was not effective in inhibiting growth of FLC in the liver and spleen. IL-2 therapy was more effective at increasing survival time in mice transplanted with non-metastatic FLC or with RBL-5 cells. In mice transplanted wth HeJ I6 fibrosarcomas, s.c. IL-2 treatment resulted in highly significant anti-tumor effect and survival of 70% of tumor-injected mice. No general correlation was found between in vitro sensitivity or resistance to the cytolytic activity of LAK cells and the anti-tumor effects observed in vivo. Subcutaneous injection of 11-1 p in mice transplanted with highly metastatic FLC resulted in a marked increase in survival time and inhibition of metastatic tumor growth in liver and spleen.

Combined treatment of IL-Ip and I L 2 produced a synergistic anti-tumor effect: 60% of mice injected with highly metastatic FLC survived. Combined IL-IhL-2 treatments exerted no anti-tumor activity either in DBN2 mice injected with antibody to Thy I .2 antigen or in nude mice, indicating that T cells play important roles during 11-1111-2 therapy. In vitro treatment of FLC with IL-IP resulted in a slight inhibition of cell multiplication, whereas even high doses of IL-2 did not affect FLC multiplication. Our results indicate that local combined treatments with IL-l and IL-2 can induce potent, hostdependent (T cell-mediated) anti-tumor effects against highly malignant tumors.